Follow Chr. Hansen A/S

Press releases View all 398 hits

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products

Press releases   •   Aug 29, 2019 13:52 UTC

​Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, announce today that they have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced in Company Announcement No. 04 on April 2, 2019.

Chr. Hansen gearer op til en bæredygtig fremtid

Chr. Hansen gearer op til en bæredygtig fremtid

Press releases   •   Aug 29, 2019 07:39 UTC

Den globale bioscience virksomhed udvider og styrker forskning- & udviklingsfaciliteterne i Hørsholm for at imødekomme den stigende efterspørgsel efter naturlige og bæredygtige produkter.

Chr. Hansen gears up for a sustainable future

Chr. Hansen gears up for a sustainable future

Press releases   •   Aug 29, 2019 07:38 UTC

Global bioscience company Chr. Hansen to expand and strengthen its research & development facilities north of Copenhagen to meet the increasing demand for natural and sustainable products.

Endnu en influenzasæson er på trapperne, men ny forskning har afsløret et hemmeligt våben, der kan nedbringe omkostningerne ved influenza-lignende sygdom

Endnu en influenzasæson er på trapperne, men ny forskning har afsløret et hemmeligt våben, der kan nedbringe omkostningerne ved influenza-lignende sygdom

Press releases   •   Aug 28, 2019 07:48 UTC

En ny sundhedsøkonomisk undersøgelse har påvist, at indtagelsen af probiotika kan bidrage til at reducere omkostningerne forbundet med influenza-lignende sygdom. Alene i USA kan indtagelsen af probiotika nedbringe antallet af sygedage med over 54 millioner dage om året, ifølge undersøgelsen.

News 1 hit

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products

News   •   Aug 29, 2019 09:16 UTC

​Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, announce today that they have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced in Company Announcement No. 04 on April 2, 2019.

Images View all 10 hits

Chr. Hansen probiotics

Chr. Hansen probiotics

License Creative Commons Attribution
Photographer / Source Chr. Hansen
Download
Size

11.1 MB • 4872 x 6496 px

Caelus logo

Caelus logo

License Creative Commons Attribution
Download
Size

113 KB • 1193 x 1224 px

World Beverage Innovation FeelGood Kefir
Chr. Hansne DVS® FRESCO® 1000NG

Chr. Hansne DVS® FRESCO® ...

License Creative Commons Attribution
Download
Size

5.18 MB • 3328 x 4992 px

Documents 4 hits

FeelGood Kefir brochure

FeelGood Kefir brochure

Documents   •   Nov 27, 2015 12:13 UTC

Chr. Hansen DVS® FRESCO® 1000NG

Chr. Hansen DVS® FRESCO® 1000NG

Documents   •   Oct 30, 2015 08:00 UTC

L. CASEI 431® Selected summaries

L. CASEI 431® Selected summaries

Documents   •   May 21, 2015 06:57 UTC

This binder provides you with summaries of selected publications on Lactobacillus paracasei subsp. paracasei L. casei 431®.

L. CASEI 431® Handout

L. CASEI 431® Handout

Documents   •   May 21, 2015 06:57 UTC

Chr. Hansen offers multiple application forms of one of our most clinically documented Probio-Tec® strains, Lactobacillus L. casei 431®.

Contacts View all 5 hits

  • Commercial Development Manager
  • DKhrJSemY@mychctr-rkhajgnshwenzm.cbaomde
  • +45 25 46 10 07

  • Regional Communications Partner
  • USbiALjbNOzf@ctphrlv-hrzanzxseptn.mvcoqjmiv
  • +14146075862

  • Head of Investor Relations
  • dkbfmaxsriub@ciqhria-hcuanawsefvn.iycojgmsi
  • +4553392250
Head of Investor Relations

  • Regional Communications Partner
  • APAC
  • SGneCHzzONgh@crhhrfj-htlanensegln.eicoqhm yu
  • +6597433100